{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=SUBPROTOCOL+A&page=2",
    "query": {
      "intervention": "SUBPROTOCOL A",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=SUBPROTOCOL+A&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-09-25T08:14:46.840Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT06162221",
      "title": "Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Non-Small Cell Lung Cancer, NSCLC",
        "KRAS, NRAS, HRAS-mutated NSCLC",
        "KRAS G12C-mutated Solid Tumors, Lung Cancer",
        "Lung Cancer Stage IV, Advanced Solid Tumor, Cancer",
        "RAS G12D-mutated NSCLC"
      ],
      "interventions": [
        {
          "name": "RMC-6291",
          "type": "DRUG"
        },
        {
          "name": "RMC-6236",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        },
        {
          "name": "Cisplatin",
          "type": "DRUG"
        },
        {
          "name": "Carboplatin",
          "type": "DRUG"
        },
        {
          "name": "Pemetrexed",
          "type": "DRUG"
        },
        {
          "name": "RMC-9805",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Revolution Medicines, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 616,
      "start_date": "2024-01-18",
      "completion_date": "2028-12",
      "has_results": false,
      "last_update_posted_date": "2026-06-30",
      "last_synced_at": "2026-09-25T08:14:46.840Z",
      "location_count": 28,
      "location_summary": "Gilbert, Arizona • Duarte, California • Irvine, California + 23 more",
      "locations": [
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06162221"
    },
    {
      "nct_id": "NCT03155620",
      "title": "Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Advanced Malignant Solid Neoplasm",
        "Ann Arbor Stage III Non-Hodgkin Lymphoma",
        "Ann Arbor Stage IV Non-Hodgkin Lymphoma",
        "Histiocytic Sarcoma",
        "Juvenile Xanthogranuloma",
        "Langerhans Cell Histiocytosis",
        "Malignant Glioma",
        "Recurrent Childhood Rhabdomyosarcoma",
        "Recurrent Ependymoma",
        "Recurrent Ewing Sarcoma",
        "Recurrent Glioma",
        "Recurrent Hepatoblastoma",
        "Recurrent Langerhans Cell Histiocytosis",
        "Recurrent Malignant Germ Cell Tumor",
        "Recurrent Malignant Solid Neoplasm",
        "Recurrent Medulloblastoma",
        "Recurrent Neuroblastoma",
        "Recurrent Non-Hodgkin Lymphoma",
        "Recurrent Osteosarcoma",
        "Recurrent Peripheral Primitive Neuroectodermal Tumor",
        "Recurrent Primary Central Nervous System Neoplasm",
        "Recurrent Rhabdoid Tumor",
        "Recurrent Soft Tissue Sarcoma",
        "Refractory Ewing Sarcoma",
        "Refractory Glioma",
        "Refractory Hepatoblastoma",
        "Refractory Langerhans Cell Histiocytosis",
        "Refractory Malignant Germ Cell Tumor",
        "Refractory Malignant Solid Neoplasm",
        "Refractory Medulloblastoma",
        "Refractory Neuroblastoma",
        "Refractory Non-Hodgkin Lymphoma",
        "Refractory Osteosarcoma",
        "Refractory Peripheral Primitive Neuroectodermal Tumor",
        "Refractory Primary Central Nervous System Neoplasm",
        "Refractory Rhabdoid Tumor",
        "Refractory Rhabdomyosarcoma",
        "Rhabdoid Tumor",
        "Stage III Osteosarcoma AJCC v7",
        "Stage III Soft Tissue Sarcoma AJCC v7",
        "Stage IV Osteosarcoma AJCC v7",
        "Stage IV Soft Tissue Sarcoma AJCC v7",
        "Stage IVA Osteosarcoma AJCC v7",
        "Stage IVB Osteosarcoma AJCC v7",
        "Wilms Tumor"
      ],
      "interventions": [
        {
          "name": "Biopsy Procedure",
          "type": "PROCEDURE"
        },
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Bone Marrow Aspiration and Biopsy",
          "type": "PROCEDURE"
        },
        {
          "name": "Bone Scan",
          "type": "PROCEDURE"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Ensartinib",
          "type": "DRUG"
        },
        {
          "name": "Erdafitinib",
          "type": "DRUG"
        },
        {
          "name": "Ivosidenib",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Larotrectinib Sulfate",
          "type": "DRUG"
        },
        {
          "name": "Magnetic Resonance Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Mutation Carrier Screening",
          "type": "PROCEDURE"
        },
        {
          "name": "Olaparib",
          "type": "DRUG"
        },
        {
          "name": "Palbociclib",
          "type": "DRUG"
        },
        {
          "name": "Pharmacological Study",
          "type": "OTHER"
        },
        {
          "name": "Positron Emission Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Radionuclide Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Samotolisib",
          "type": "DRUG"
        },
        {
          "name": "Selpercatinib",
          "type": "DRUG"
        },
        {
          "name": "Selumetinib Sulfate",
          "type": "DRUG"
        },
        {
          "name": "Tazemetostat",
          "type": "DRUG"
        },
        {
          "name": "Tipifarnib",
          "type": "DRUG"
        },
        {
          "name": "Ulixertinib",
          "type": "DRUG"
        },
        {
          "name": "Vemurafenib",
          "type": "DRUG"
        },
        {
          "name": "X-Ray Imaging",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Months",
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "12 Months to 21 Years"
      },
      "enrollment_count": 1377,
      "start_date": "2017-07-31",
      "completion_date": "2027-01-06",
      "has_results": true,
      "last_update_posted_date": "2026-07-24",
      "last_synced_at": "2026-09-25T08:14:46.840Z",
      "location_count": 168,
      "location_summary": "Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 126 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Mesa",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03155620"
    },
    {
      "nct_id": "NCT06385483",
      "title": "Testing Afatinib as Potentially Targeted Treatment in Cancers With EGFR Genetic Changes (MATCH - Subprotocol A)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Advanced Lymphoma",
        "Advanced Malignant Solid Neoplasm",
        "Refractory Lymphoma",
        "Refractory Malignant Solid Neoplasm",
        "Refractory Multiple Myeloma"
      ],
      "interventions": [
        {
          "name": "Afatinib",
          "type": "DRUG"
        },
        {
          "name": "Biopsy Procedure",
          "type": "PROCEDURE"
        },
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Echocardiography Test",
          "type": "PROCEDURE"
        },
        {
          "name": "Magnetic Resonance Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Radionuclide Imaging",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 19,
      "start_date": "2018-02-28",
      "completion_date": "2027-01-15",
      "has_results": true,
      "last_update_posted_date": "2026-07-17",
      "last_synced_at": "2026-09-25T08:14:46.840Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06385483"
    },
    {
      "nct_id": "NCT03698994",
      "title": "Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Advanced Malignant Solid Neoplasm",
        "Recurrent Ependymal Tumor",
        "Recurrent Ewing Sarcoma",
        "Recurrent Glioma",
        "Recurrent Hepatoblastoma",
        "Recurrent Histiocytic and Dendritic Cell Neoplasm",
        "Recurrent Langerhans Cell Histiocytosis",
        "Recurrent Malignant Germ Cell Tumor",
        "Recurrent Malignant Solid Neoplasm",
        "Recurrent Medulloblastoma",
        "Recurrent Neuroblastoma",
        "Recurrent Non-Hodgkin Lymphoma",
        "Recurrent Osteosarcoma",
        "Recurrent Peripheral Primitive Neuroectodermal Tumor",
        "Recurrent Primary Malignant Central Nervous System Neoplasm",
        "Recurrent Rhabdoid Tumor",
        "Recurrent Rhabdomyosarcoma",
        "Recurrent Soft Tissue Sarcoma",
        "Refractory Ependymoma",
        "Refractory Ewing Sarcoma",
        "Refractory Glioma",
        "Refractory Hepatoblastoma",
        "Refractory Histiocytic and Dendritic Cell Neoplasm",
        "Refractory Langerhans Cell Histiocytosis",
        "Refractory Malignant Germ Cell Tumor",
        "Refractory Malignant Solid Neoplasm",
        "Refractory Medulloblastoma",
        "Refractory Neuroblastoma",
        "Refractory Non-Hodgkin Lymphoma",
        "Refractory Osteosarcoma",
        "Refractory Peripheral Primitive Neuroectodermal Tumor",
        "Refractory Primary Malignant Central Nervous System Neoplasm",
        "Refractory Rhabdoid Tumor",
        "Refractory Rhabdomyosarcoma",
        "Refractory Soft Tissue Sarcoma",
        "Wilms Tumor"
      ],
      "interventions": [
        {
          "name": "Pharmacokinetic Study",
          "type": "OTHER"
        },
        {
          "name": "Ulixertinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "OTHER",
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Months",
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "12 Months to 21 Years"
      },
      "enrollment_count": 20,
      "start_date": "2018-11-14",
      "completion_date": "2027-03-30",
      "has_results": true,
      "last_update_posted_date": "2026-09-21",
      "last_synced_at": "2026-09-25T08:14:46.840Z",
      "location_count": 105,
      "location_summary": "Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 82 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Mesa",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03698994"
    },
    {
      "nct_id": "NCT04439331",
      "title": "Testing VS-6063 (Defactinib) as a Potential Targeted Treatment in Cancers With NF2 Genetic Changes (MATCH-Subprotocol U)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Advanced Lymphoma",
        "Advanced Malignant Solid Neoplasm",
        "Hematopoietic and Lymphoid Cell Neoplasm",
        "Refractory Lymphoma",
        "Refractory Malignant Solid Neoplasm",
        "Refractory Multiple Myeloma"
      ],
      "interventions": [
        {
          "name": "Defactinib Hydrochloride",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 35,
      "start_date": "2015-11-19",
      "completion_date": "2027-01-15",
      "has_results": true,
      "last_update_posted_date": "2026-05-07",
      "last_synced_at": "2026-09-25T08:14:46.840Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04439331"
    },
    {
      "nct_id": "NCT03220035",
      "title": "Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Advanced Malignant Solid Neoplasm",
        "Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma",
        "Ann Arbor Stage IV Childhood Non-Hodgkin Lymphoma",
        "Ependymoma",
        "Ewing Sarcoma",
        "Hepatoblastoma",
        "Langerhans Cell Histiocytosis",
        "Malignant Germ Cell Tumor",
        "Malignant Glioma",
        "Osteosarcoma",
        "Peripheral Primitive Neuroectodermal Tumor",
        "Recurrent Childhood Central Nervous System Neoplasm",
        "Recurrent Childhood Non-Hodgkin Lymphoma",
        "Recurrent Malignant Solid Neoplasm",
        "Recurrent Neuroblastoma",
        "Refractory Malignant Solid Neoplasm",
        "Refractory Neuroblastoma",
        "Refractory Non-Hodgkin Lymphoma",
        "Refractory Primary Central Nervous System Neoplasm",
        "Rhabdoid Tumor",
        "Rhabdomyosarcoma",
        "Soft Tissue Sarcoma",
        "Wilms Tumor"
      ],
      "interventions": [
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Vemurafenib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "OTHER",
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Months",
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "12 Months to 21 Years"
      },
      "enrollment_count": 4,
      "start_date": "2017-11-08",
      "completion_date": "2024-12-31",
      "has_results": true,
      "last_update_posted_date": "2025-01-27",
      "last_synced_at": "2026-09-25T08:14:46.840Z",
      "location_count": 114,
      "location_summary": "Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 90 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Mesa",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03220035"
    },
    {
      "nct_id": "NCT07775976",
      "title": "Cor360: Clinician-Facing Broad-Spectrum Cardiac Phenotyping and Risk Assessment Using COR® Wearable ECG to Inform Outcomes-Oriented Care Pathways",
      "overall_status": "ENROLLING_BY_INVITATION",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Cardiovascular Diseases",
        "Cardiovascular Diseases Risk",
        "Cardiac Conduction System Disease",
        "Bundle/Fascicular Abnormalities",
        "His-Purkinje Disease",
        "Arrhythmias, Cardiac",
        "Rhythm Phenotypes",
        "Myocardial Ischemia",
        "Syncope",
        "Syncope Recurrent",
        "Syncope and Collapse",
        "Seizure Disorder",
        "Sleep Apnea Syndrome, Obstructive",
        "Decision Support Systems, Clinical",
        "Heart Failure - NYHA II - IV",
        "Heart Failure (for Example, Fluid Overload)",
        "HRV",
        "Cardiopulmonary",
        "Sudden Cardiac Arrest",
        "Cardiac Arrest (CA)",
        "Ventricular Arrhythmias and Cardiac Arrest",
        "Ventricular Fibrillation",
        "QT Dispersion",
        "Atrial Cardiomyopathy"
      ],
      "interventions": [
        {
          "name": "COR Wearable ECG Monitoring",
          "type": "DEVICE"
        },
        {
          "name": "Cor360 Clinician-Facing Decision-Aid Reporting",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DEVICE",
        "OTHER"
      ],
      "sponsor": "Peerbridge Health, Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1000,
      "start_date": "2026-08-20",
      "completion_date": "2030-06-17",
      "has_results": false,
      "last_update_posted_date": "2026-08-21",
      "last_synced_at": "2026-09-25T08:14:46.840Z",
      "location_count": 2,
      "location_summary": "Pasadena, California • Nashville, Tennessee",
      "locations": [
        {
          "city": "Pasadena",
          "state": "California"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07775976"
    },
    {
      "nct_id": "NCT06445062",
      "title": "Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Colorectal Cancer",
        "CRC",
        "Pancreatic Ductal Adenocarcinoma",
        "PDAC",
        "Gastrointestinal Cancer",
        "Metastatic Pancreatic Ductal Adenocarcinoma"
      ],
      "interventions": [
        {
          "name": "RMC-6236",
          "type": "DRUG"
        },
        {
          "name": "mFOLFOX6 regimen",
          "type": "DRUG"
        },
        {
          "name": "bevacizumab",
          "type": "DRUG"
        },
        {
          "name": "mFOLFIRINOX regimen",
          "type": "DRUG"
        },
        {
          "name": "cetuximab",
          "type": "DRUG"
        },
        {
          "name": "gemcitabine",
          "type": "DRUG"
        },
        {
          "name": "nab-paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "RMC-9805",
          "type": "DRUG"
        },
        {
          "name": "FOLFIRI regimen",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Revolution Medicines, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1130,
      "start_date": "2024-05-24",
      "completion_date": "2030-03-30",
      "has_results": false,
      "last_update_posted_date": "2026-09-22",
      "last_synced_at": "2026-09-25T08:14:46.840Z",
      "location_count": 32,
      "location_summary": "Chandler, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 24 more",
      "locations": [
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06445062"
    },
    {
      "nct_id": "NCT04439123",
      "title": "Testing AZD5363 as a Potential Targeted Treatment in Cancers With AKT Genetic Changes (MATCH-Subprotocol Y)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Advanced Lymphoma",
        "Advanced Malignant Solid Neoplasm",
        "Hematopoietic and Lymphoid Cell Neoplasm",
        "Refractory Lymphoma",
        "Refractory Malignant Solid Neoplasm",
        "Refractory Multiple Myeloma"
      ],
      "interventions": [
        {
          "name": "Capivasertib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 35,
      "start_date": "2016-05-31",
      "completion_date": "2027-03-31",
      "has_results": true,
      "last_update_posted_date": "2026-05-06",
      "last_synced_at": "2026-09-25T08:14:46.840Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04439123"
    },
    {
      "nct_id": "NCT03213678",
      "title": "Samotolisib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Advanced Malignant Solid Neoplasm",
        "Ann Arbor Stage III Non-Hodgkin Lymphoma",
        "Ann Arbor Stage IV Non-Hodgkin Lymphoma",
        "Malignant Glioma",
        "Recurrent Ependymoma",
        "Recurrent Ewing Sarcoma",
        "Recurrent Glioma",
        "Recurrent Hepatoblastoma",
        "Recurrent Langerhans Cell Histiocytosis",
        "Recurrent Malignant Germ Cell Tumor",
        "Recurrent Malignant Solid Neoplasm",
        "Recurrent Medulloblastoma",
        "Recurrent Neuroblastoma",
        "Recurrent Non-Hodgkin Lymphoma",
        "Recurrent Osteosarcoma",
        "Recurrent Peripheral Primitive Neuroectodermal Tumor",
        "Recurrent Primary Central Nervous System Neoplasm",
        "Recurrent Rhabdomyosarcoma",
        "Recurrent Soft Tissue Sarcoma",
        "Refractory Langerhans Cell Histiocytosis",
        "Refractory Malignant Germ Cell Tumor",
        "Refractory Malignant Solid Neoplasm",
        "Refractory Neuroblastoma",
        "Refractory Non-Hodgkin Lymphoma",
        "Refractory Primary Central Nervous System Neoplasm",
        "Rhabdoid Tumor",
        "Stage III Osteosarcoma AJCC v7",
        "Stage III Soft Tissue Sarcoma AJCC v7",
        "Stage IV Osteosarcoma AJCC v7",
        "Stage IV Soft Tissue Sarcoma AJCC v7",
        "Stage IVA Osteosarcoma AJCC v7",
        "Stage IVB Osteosarcoma AJCC v7",
        "Wilms Tumor"
      ],
      "interventions": [
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "FDG-Positron Emission Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Magnetic Resonance Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Samotolisib",
          "type": "DRUG"
        },
        {
          "name": "X-Ray Imaging",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Months",
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "12 Months to 21 Years"
      },
      "enrollment_count": 18,
      "start_date": "2017-11-28",
      "completion_date": "2024-12-31",
      "has_results": true,
      "last_update_posted_date": "2026-04-21",
      "last_synced_at": "2026-09-25T08:14:46.840Z",
      "location_count": 125,
      "location_summary": "Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 96 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Mesa",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03213678"
    }
  ]
}